Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014 Sep; 16(9):1257-69.
-
Antigens, CD19
-
Cancer Vaccines
-
Cell Line, Tumor
-
Cell Proliferation
-
Culture Media, Serum-Free
-
Cytotoxicity, Immunologic
-
DNA Transposable Elements
-
Drug Resistance, Neoplasm
-
Genetic Engineering
-
Genetic Vectors
-
Humans
-
Immunotherapy, Adoptive
-
Interleukin-15
-
Interleukin-2
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Mutation
-
Protein Kinase Inhibitors
-
Receptors, Antigen, T-Cell
-
Recombinant Fusion Proteins
-
T-Lymphocytes
-
TNF-Related Apoptosis-Inducing Ligand
-
Up-Regulation